Posted by Michael Wonder on 02 Apr 2020
Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in UK
2 April 2020 - The pair of phase 3 trials will take place across 15 clinical sites in the UK.
Gilead Sciences has started a pair of phase 3 trials of its experimental antiviral drug remdesivir in the UK in patients with moderate-to-severe COVID-19, with results expected within weeks.
The two studies will take place across 15 clinical sites in the UK, as the country sees its biggest daily increase in deaths from coronavirus of 563, taking the total number of fatalities in the country to 2,352.
